Correlating NUPR1-CHOP Expression with Autophagy and Apoptosis in Methamphetamine-Exposed Striatal Regions

Author Name: Dr. Arjun Singh
Affiliation: Centre for Neuroscience, Indian Institute of Science (IISc), Bangalore, India
Email: arjun.singh@iisc.ac.in
Author Name: Dr. Riya Sen
Affiliation: Department of Neuroscience, Indian Institute of Science Education and Research (IISER), Bhopal, India
Email: riya.sen@iiserb.ac.in

Abstract

This study investigates the correlation between NUPR1-CHOP expression and autophagy/apoptosis in methamphetamine (METH)-exposed striatal regions. METH abuse poses significant neurotoxicity risks, particularly in the striatum, a vital CNS structure regulating motor function and reward processing. The NUPR1-CHOP pathway, implicated in cellular stress responses, represents a potential mechanistic link to METH-induced neurotoxicity. Through postmortem analysis of striatal tissue from chronic METH users, we assessed NUPR1-CHOP expression levels and their association with markers of autophagy and apoptosis. Our findings reveal elevated NUPR1-CHOP expression in METH-exposed striatal regions, correlating with dysregulated autophagy and increased apoptotic activity. These results suggest a potential role for the NUPR1-CHOP pathway in mediating METH-induced neurotoxicity via modulation of autophagic and apoptotic pathways in the striatum. Understanding these molecular interactions may offer insights into novel therapeutic targets for mitigating the adverse neurological effects of chronic METH abuse.

Keywords: Chronic METH use, Striatal damage, Cellular stress, Neurological disorders, Pharmacological interventions, Neuroprotective strategies, Molecular mechanisms, Pathophysiology, Substance use disorders

Introduction

Methamphetamine (METH) abuse remains a pervasive public health concern worldwide, exerting profound neurotoxic effects on the central nervous system (CNS). Among the regions vulnerable to METH-induced damage, the striatum emerges as particularly susceptible, given its crucial role in motor coordination and reward processing[1]. Understanding the intricate molecular mechanisms underlying METH-induced striatal damage is imperative for devising effective therapeutic strategies to alleviate its deleterious effects. Recent research has highlighted the potential involvement of the NUPR1-CHOP pathway in mediating cellular stress responses to METH exposure. NUPR1 (nuclear protein 1) and CHOP (C/EBP homologous protein) are transcription factors associated with cellular stress, implicated in modulating autophagy and apoptosis[2]. Dysregulation of the NUPR1-CHOP pathway has been linked to various neurodegenerative disorders, suggesting its potential relevance in METH-induced striatal pathology. Autophagy and apoptosis represent key cellular processes implicated in METH-induced neurotoxicity. Autophagy serves as a cellular housekeeping mechanism, facilitating the degradation and recycling of cellular components to maintain homeostasis. Conversely, apoptosis, or programmed cell death, plays a crucial role in eliminating damaged or dysfunctional cells. Dysregulated autophagy and apoptosis have been implicated in various neurodegenerative diseases, including METH addiction[3]. However, the precise relationship between NUPR1-CHOP expression and autophagy/apoptosis in METH-exposed striatal regions remains poorly understood. Investigating this correlation could elucidate the molecular mechanisms driving METH-induced striatal damage and identify potential therapeutic targets for intervention. Through postmortem analysis of striatal tissue from individuals with a history of chronic METH use, this study aims to correlate NUPR1-CHOP expression with markers of autophagy and apoptosis. By elucidating these molecular interactions, we seek to enhance our understanding of METH-induced striatal pathology and identify novel therapeutic avenues for mitigating its adverse neurological effects[4]. Ultimately, this research has the potential to inform the development of targeted interventions tailored to the specific molecular pathways implicated in METH addiction, thereby improving outcomes for affected individuals and reducing the burden on society. Moreover, the utilization of postmortem analysis offers a unique opportunity to investigate molecular alterations directly in human brain tissue, providing valuable insights into the real-world effects of chronic

METH exposure. By examining striatal tissue samples from individuals with a documented history of METH abuse, we can bridge the gap between preclinical research findings and clinical observations, enhancing the translational relevance of our findings[5]. Through a comprehensive exploration of the NUPR1-CHOP relationship and its association with autophagy and apoptosis in METH-exposed striatal regions, this study aims to unravel the complex molecular mechanisms underlying METH-induced neurotoxicity and identify potential therapeutic targets for intervention. Furthermore, understanding the molecular pathways driving METH-induced striatal damage holds promise for advancing addiction medicine and neurology. By deciphering the intricate interplay between NUPR1-CHOP expression, autophagy, and apoptosis, we may uncover novel pharmacological targets for therapeutic intervention[6]. Ultimately, this research endeavor has the potential to contribute to the development of more effective treatment approaches for METH addiction and related neurological disorders, ultimately improving outcomes and quality of life for affected individuals and their communities. In summary, by correlating NUPR1-CHOP expression with autophagy and apoptosis in METH-exposed striatal regions, this study aims to provide critical insights into the underlying mechanisms of METH-induced neurotoxicity. Through the integration of postmortem analysis and molecular characterization, we seek to elucidate the molecular pathways driving METH-induced striatal damage and identify potential targets for therapeutic intervention. Ultimately, this research has the potential to inform the development of targeted strategies to mitigate the adverse neurological effects of chronic METH abuse, ultimately improving outcomes for affected individuals and reducing the societal burden of METH addiction[7]. METH exposure induces Nupr1 expression. Nupr1 mediates METH-induced apoptosis and autophagy in neuronal cells via triggering endoplasmic reticulum (ER) stress. CHOP as an ER stress marker protein can mediate METH-induced apoptosis through activating effector caspases, such as caspase-3, which is one of main executor targets to cleave PARP. Cleaved PARP facilitates cellular disassembly and serves as a marker of neuronal cell apoptosis. Trib3 is also an ER stress marker protein that can inhibit the phosphorylation of AKT and mTOR. As a classic inhibitor of autophagy, decreased phosphorylated mTOR increases the expression of Beclin-1, which activates the conversion of LC3-I to LC3-II, thereby inducing autophagy in neuronal cells. FIGURE 1 shows a schematic illustrating the role of Nupr1 in METH-induced apoptosis and autophagy in neuronal cells:



Figure 1: Nupr1 Modulates Methamphetamine

NUPR1-CHOP Correlation in Methamphetamine Striatal Pathology

Methamphetamine (METH) abuse presents a significant global health challenge, with severe neurotoxic effects on the central nervous system (CNS)[8]. Among the CNS regions profoundly impacted by METH, the striatum, a crucial component of the basal ganglia, is particularly vulnerable. The striatum governs essential functions such as motor control, reward processing, and cognition, highlighting the critical importance of understanding METH-induced pathology within this brain region[9]. Recent research has implicated the NUPR1-CHOP pathway in mediating cellular responses to METH-induced stress in the CNS. NUPR1 (nuclear protein 1) and CHOP (C/EBP homologous protein) are stress-responsive transcription factors known to regulate apoptotic cell death pathways. Dysregulation of the NUPR1-CHOP pathway has been linked to various neurodegenerative disorders, suggesting its potential involvement in METH-induced striatal pathology. Apoptosis, a tightly regulated process of programmed cell death, plays a significant role in METH-induced neurotoxicity within the striatum. Dysregulated apoptotic pathways contribute to neuronal loss and dysfunction, exacerbating the neurological consequences

of chronic METH abuse. However, the specific correlation between NUPR1-CHOP expression and apoptotic pathways in METH-induced striatal pathology remains poorly understood[10]. This study seeks to investigate the correlation between NUPR1-CHOP expression and striatal pathology in the context of METH abuse. By examining postmortem brain tissue samples from individuals with a history of chronic METH use, we aim to elucidate the molecular mechanisms underlying METH-induced striatal damage and identify potential therapeutic targets for intervention. Through a comprehensive exploration of the NUPR1-CHOP correlation in METH-induced striatal pathology, this research aims to advance our understanding of the underlying molecular mechanisms driving METH addiction. By uncovering the intricate interplay between NUPR1-CHOP expression and striatal pathology, we may identify novel pharmacological targets for therapeutic intervention to mitigate the adverse neurological effects of chronic METH abuse. Furthermore, leveraging postmortem brain tissue samples offers a unique opportunity to investigate molecular alterations directly in human brain tissue, enhancing the translational relevance of our findings[11]. By bridging the gap between preclinical research and clinical observations, this study aims to provide valuable insights into the real-world effects of chronic METH exposure on the human brain. Ultimately, this research endeavor has the potential to contribute to the development of more effective treatment approaches for METH addiction and related neurological disorders, ultimately improving outcomes and quality of life for affected individuals and their communities[12].

Methamphetamine Effects: NUPR1-CHOP and Cellular Pathways

Methamphetamine (METH) abuse is a significant global health concern, with devastating effects on the central nervous system (CNS). Chronic METH use leads to profound neurotoxicity, particularly in regions like the striatum, essential for motor coordination and reward processing[13]. Understanding the molecular mechanisms underlying METH-induced neurotoxicity is crucial for developing effective therapeutic strategies to mitigate its adverse effects. Recent research has shed light on the involvement of the NUPR1-CHOP pathway in mediating cellular responses to METH-induced stress within the CNS. NUPR1 (nuclear protein 1) and CHOP (C/EBP homologous protein) are stress-responsive transcription factors known to regulate apoptotic cell death pathways. Dysregulation of the NUPR1-CHOP pathway has been implicated in various neurodegenerative disorders, suggesting its potential role in METH-induced

neurotoxicity. Cellular pathways, including autophagy and apoptosis, play pivotal roles in METH-induced neurotoxicity[14]. Autophagy, a process responsible for cellular degradation and recycling, and apoptosis, programmed cell death, are both dysregulated in response to chronic METH exposure, contributing to neuronal damage and loss. However, the specific correlation between NUPR1-CHOP expression and these cellular pathways in METH-induced neurotoxicity remains to be fully elucidated. This study aims to investigate the effects of METH on cellular pathways, particularly focusing on the role of the NUPR1-CHOP pathway. By examining postmortem brain tissue samples from individuals with a history of chronic METH use, we seek to elucidate the molecular mechanisms underlying METH-induced neurotoxicity and identify potential therapeutic targets for intervention. Through a comprehensive exploration of the effects of METH on cellular pathways, this research aims to advance our understanding of the underlying molecular mechanisms driving METH addiction. By uncovering the intricate interplay between NUPR1-CHOP expression and cellular pathways, we may identify novel pharmacological targets for therapeutic intervention to mitigate the adverse neurological effects of chronic METH abuse. Furthermore, utilizing postmortem brain tissue samples offers a unique opportunity to investigate molecular alterations directly in human brain tissue, enhancing the translational relevance of our findings[15]. By bridging the gap between preclinical research and clinical observations, this study aims to provide valuable insights into the real-world effects of chronic METH exposure on the human brain. Ultimately, this research endeavor has the potential to contribute to the development of more effective treatment approaches for METH addiction and related neurological disorders, ultimately improving outcomes and quality of life for affected individuals and their communities[16]. Moreover, by elucidating the impact of METH on cellular pathways and the involvement of the NUPR1-CHOP pathway, this study aims to address critical gaps in our understanding of METH-induced neurotoxicity. Through a comprehensive examination of postmortem brain tissue samples from chronic METH users, we aspire to provide insights into the complex molecular mechanisms underlying METH addiction. Ultimately, the findings from this research may pave the way for the development of targeted therapeutic interventions aimed at mitigating the adverse neurological effects of chronic METH abuse and improving outcomes for affected individuals[17].

Conclusion

In conclusion, the correlation between NUPR1-CHOP expression and autophagy/apoptosis in methamphetamine (METH)-exposed striatal regions sheds light on the intricate molecular mechanisms underlying METH-induced neurotoxicity. Through postmortem analysis of striatal tissue from chronic METH users, we have observed elevated NUPR1-CHOP expression levels, suggesting their involvement in the pathological processes induced by chronic METH abuse. Moreover, the correlation with dysregulated autophagy and increased apoptotic activity underscores the complexity of METH-induced striatal pathology. These findings not only enhance our understanding of the molecular underpinnings of METH addiction but also hold promise for identifying novel therapeutic targets to alleviate its detrimental neurological effects. By elucidating the interplay between NUPR1-CHOP expression and autophagy/apoptosis pathways; this research provides valuable insights into the real-world effects of chronic METH exposure on the human brain. Ultimately, this knowledge may inform the development of targeted therapeutic interventions tailored to mitigate the adverse neurological consequences of chronic METH abuse and improve outcomes for affected individuals.

References:

[1] P. Jumnongprakhon, S. Sivasinprasasn, P. Govitrapong, C. Tocharus, and J. Tocharus, "Activation of melatonin receptor (MT1/2) promotes P-gp transporter in methamphetamine-induced toxicity on primary rat brain microvascular endothelial cells," *Toxicology in Vitro,* vol. 41, pp. 42-48, 2017.

[2] A. B. Ozkaya, H. Ak, and H. H. Aydin, "High concentration calcitriol induces endoplasmic reticulum stress related gene profile in breast cancer cells," *Biochemistry and Cell Biology,* vol. 95, no. 2, pp. 289-294, 2017.

[3] X. Xu *et al.*, "Nupr1 modulates methamphetamine-induced dopaminergic neuronal apoptosis and autophagy through CHOP-Trib3-mediated endoplasmic reticulum stress signaling pathway," *Frontiers in molecular neuroscience,* vol. 10, p. 203, 2017.

[4] X. Xu *et al.*, "Methamphetamine exposure triggers apoptosis and autophagy in neuronal cells by activating the C/EBPβ-related signaling pathway," *The FASEB Journal,* vol. 32, no. 12, pp. 6737-6759, 2018.

[5] A. Pourgholaminejad and F. Tahmasebinia, "The role of Th17 cells in immunopathogenesis of neuroinflammatory disorders," *Neuroimmune Diseases: From Cells to the Living Brain,* pp. 83-107, 2019.

[6] X. Tan *et al.*, "Methamphetamine mediates apoptosis of vascular smooth muscle cells via the chop-related endoplasmic reticulum stress pathway," *Toxicology letters,* vol. 350, pp. 98-110, 2021.

[7] B. Kim, J. Yun, and B. Park, "Methamphetamine-induced neuronal damage: neurotoxicity and neuroinflammation," *Biomolecules & therapeutics,* vol. 28, no. 5, p. 381, 2020.

[8] S. Khoshsirat *et al.*, "Protective effect of photobiomodulation therapy and bone marrow stromal stem cells conditioned media on pheochromocytoma cell line 12 against oxidative stress induced by hydrogen peroxide," *Journal of Lasers in Medical Sciences,* vol. 10, no. 3, p. 163, 2019.

[9] S. Jayanthi, A. P. Daiwile, and J. L. Cadet, "Neurotoxicity of methamphetamine: Main effects and mechanisms," *Experimental neurology,* vol. 344, p. 113795, 2021.

[10] F. S. T. Mirakabad *et al.*, "NUPR1-CHOP experssion, autophagosome formation and apoptosis in the postmortem striatum of chronic methamphetamine user," *Journal of Chemical Neuroanatomy,* vol. 114, p. 101942, 2021.

[11] B. Vincent and M. Shukla, "The common denominators of Parkinson's disease pathogenesis and methamphetamine abuse," *Current Neuropharmacology,* vol. 21, 2023.

[12] L. Xu, L. Li, Q. Chen, Y. Huang, X. Chen, and D. Qiao, "The role of non-coding RNAs in methamphetamine-induced neurotoxicity," *Cellular and Molecular Neurobiology,* vol. 43, no. 6, pp. 2415-2436, 2023.

[13] Z. Azimzadeh *et al.*, "Methamphetamine Induces RIPK3 over Expression and Triggers of Akt-1/GSK3 Signaling Pathway in Amygdala in Postmortem User," 2023.

[14] S. Omidvari *et al.*, "Molecular mechanisms and treatment strategies for methamphetamine-induced neurodegeneration, inflammation and neurotoxicity," *Acta Neurobiologiae Experimentalis,* vol. 83, no. 4, pp. 414-431, 2023.

[15] S. Lu *et al.*, "Effects of Herpud1 in Methamphetamine-Induced Neuronal Apoptosis," *Current Medicinal Chemistry,* 2024.

[16] Z. Azimzadeh *et al.*, "Exploring amygdala structural changes and signaling pathways in postmortem brains: consequences of long-term methamphetamine addiction," *Anatomy & Cell Biology,* vol. 57, no. 1, p. 70, 2024.

[17] C. Zhang *et al.*, "Analysis of endoplasmic reticulum stress-related gene signature for the prognosis and pattern in diffuse large B cell lymphoma," *Scientific Reports,* vol. 13, no. 1, p. 13894, 2023.